Case Control Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2024; 16(4): 601-611
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.601
Expression and clinical significance of short-chain fatty acids in patients with intrahepatic cholestasis of pregnancy
Shuai-Jun Ren, Jia-Ting Feng, Ting Xiang, Cai-Lian Liao, Yu-Ping Zhou, Rong-Rong Xuan
Shuai-Jun Ren, Jia-Ting Feng, Ting Xiang, Cai-Lian Liao, Rong-Rong Xuan, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Ningbo University, Ningbo 315100, Zhejiang Province, China
Jia-Ting Feng, Ting Xiang, Cai-Lian Liao, Health Science Center, Ningbo University, Ningbo 315211, Zhejiang Province, China
Yu-Ping Zhou, Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315211, Zhejiang Province, China
Yu-Ping Zhou, Institute of Digestive Disease, Ningbo University, Ningbo 315020, Zhejiang Province, China
Author contributions: Ren SJ, Zhou YP and Xuan RR designed the research; Ren SJ, Feng JT, Xiang T and Liao CL performed the research; Feng JT, Xiang T and Liao CL analyzed the data; Ren SJ, Zhou YP and Xuan RR wrote the paper; all authors participated in primary and final drafting; all authors have read and approve the final manuscript; all authors significantly contributed to the study.
Supported by The Medical and Health Research Project of Zhejiang Province, No. 2023KY1105; and the Traditional Chinese Medical and Health Research Project of Zhejiang Province, No. 2022ZB328.
Institutional review board statement: The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution and it conforms to the provisions of the Declaration of Helsinki. Committee of The First Affiliated Hospital of ningbo university, Approval No. KY20220912. All informed consent was obtained from the subjects.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
Data sharing statement: The data that support the findings of this study are available from the corresponding author at fyxuanrongrong@nbu.edu.cn upon reasonable request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rong-Rong Xuan, MAMS, Doctor, Teacher, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo 315100, Zhejiang Province, China. fyxuanrongrong@nbu.edu.cn
Received: November 13, 2023
Peer-review started: November 13, 2023
First decision: January 23, 2024
Revised: February 4, 2024
Accepted: March 7, 2024
Article in press: March 7, 2024
Published online: April 27, 2024
Processing time: 162 Days and 17.2 Hours
ARTICLE HIGHLIGHTS
Research background

Intrahepatic cholestasis of pregnancy (ICP) is a liver condition specific to pregnancy. Short-chain fatty acids (SCFAs), important metabolites produced by the gut microbiota, are significantly linked to several pregnancy complications.

Research motivation

However, the metabolic profile of SCFAs in patients with ICP is still uncertain.

Research objectives

The study aimed to examine the correlation between maternal and umbilical blood SCFAs and investigate the changes in SCFAs in patients with ICP and their offspring. Additionally, the research sought to assess the clinical significance and diagnostic value of these SCFAs. Ultimately, the study aimed to identify novel biomarkers for diagnosing and treating ICP by focusing on gut microbiota metabolites.

Research methods

Therefore, in this study, we utilized targeted metabolomics technology to analyze SCFAs in the maternal and cord blood of patients with ICP and normal pregnant (NP) women.

Research results

The study revealed that maternal serum SCFAs in both the ICP and NP groups showed significantly higher levels of acetic acid, propionic acid, and butyric acid compared to other SCFAs. In umbilical cord blood, acetic and propionic acids were found to be the most abundant, with similar levels of butyric acid, isobutyric acid, and caproic acid, while isovaleric acid and valeric acid levels were the lowest. Furthermore, the correlation analysis indicated a negative correlation between both acetic acid and caproic acid in maternal and cord blood, and total bile acids in peripheral blood.

Research conclusions

Significant alterations were observed in the SCFAs of maternal serum and cord blood in the ICP group, compared with the NP group. It is notable that the SCFA levels in maternal serum and cord blood were significantly positively correlated in the ICP group. Additionally, certain maternal serum SCFAs, specifically caproic and acetic acids, exhibited excellent diagnostic efficiency for ICP.

Research perspectives

Additional in vivo and in vitro experiments are needed to clarify the mechanisms of action of SCFAs, establishing a strong theoretical basis for their use as diagnostic and therapeutic targets for ICP.